肠道微生物群疗法防治复发性艰难梭菌感染研究进展

doi:10.3969/j.issn.1004-583X.2022.08.016

摘要/Abstract

摘要：

在抗菌药物和后抗菌药物时代,艰难梭菌感染的发病率、复发率和死亡率仍显著上升,是目前重要的医院获得性感染之一。反复艰难梭菌感染是诊治过程中的一大难点,3次或3次以上感染后复发率高达60%。正常肠道的菌群破坏是复发性艰难梭菌感染的重要发病环节。因此,在重建肠道稳态上发展而来的微生物群疗法似乎可以有效地预防和治疗复发性艰难梭菌感染。本文对粪便微生物群移植、标准化微生物群疗法、益生菌、非产毒型艰难梭菌在复发性艰难梭菌感染防治中的研究进展进行综述,旨在为临床诊治提供依据。

中图分类号:

R516

王晶霞, 汤灵玲. 肠道微生物群疗法防治复发性艰难梭菌感染研究进展[J]. 临床荟萃, 2022, 37(8): 759-763.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://huicui.hebmu.edu.cn/CN/10.3969/j.issn.1004-583X.2022.08.016

https://huicui.hebmu.edu.cn/CN/Y2022/V37/I8/759

参考文献 45

[1]	Magee La, Singer J, Von Dadelszen P, et al. Less-tight versus tight control of hypertension in pregnancy[J]. N Engl J Med, 2015, 372(24): 2366-2368. doi: 10.1056/NEJMc1503870 URL
[2]	Rao K, Malani PN. Diagnosis and treatment of Clostridioides (Clostridium) difficile infection in adults in 2020[J]. JAMA, 2020, 323(14): 1403-1404. doi: 10.1001/jama.2019.3849 pmid: 32150234
[3]	Juul FE, Garborg K, Bretthauer M, et al. Fecal microbiota transplantation for primary Clostridium difficile infection[J]. N Engl J Med, 2018, 378(26): 2535-2536. doi: 10.1056/NEJMc1803103 URL
[4]	Picca SM. Hyperammonemia after blood transfusion[J]. Ann Intern Med, 2018, 168(4): 306. doi: 10.7326/L17-0641 pmid: 29459968
[5]	Kelly CP. Can we identify patients at high risk of recurrent Clostridium difficile infection?[J]. Clin Microbiol Infect, 2012, 18(Suppl 6):21-27.
[6]	Song JH, Kim YS. Recurrent Clostridium difficile infection: Risk factors, treatment, and prevention[J]. Gut Liver, 2019, 13(1): 16-24. doi: 10.5009/gnl18071 URL
[7]	Mcdonald LC, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA)[J]. Clin Infect Dis, 2018, 66(7): 987-994. doi: 10.1093/cid/ciy149 pmid: 29562266
[8]	Chumbler NM, Rutherford SA, Zhang Z, et al. Crystal structure of Clostridium difficile toxin A[J]. Nat Microbiol, 2016, 1:15002. doi: 10.1038/nmicrobiol.2015.2 pmid: 27571750
[9]	Gupta A, Saha S, Khanna S. Therapies to modulate gut microbiota: Past, present and future[J]. World J Gastroenterol, 2020, 26(8): 777-788. doi: 10.3748/wjg.v26.i8.777 URL
[10]	Saha S, Khanna S. Management of Clostridioides difficile colitis: Insights for the gastroenterologist[J]. Therap Adv Gastroenterol, 2019, 5(12): 1756284819847651.
[11]	Britton GJ, Contijoch EJ, Spindler MP, et al. Defined microbiota transplant restores Th17/RORgammat(+) regulatory T cell balance in mice colonized with inflammatory bowel disease microbiotas[J]. Proc Natl Acad Sci U S A, 2020, 117(35): 21536-21545. doi: 10.1073/pnas.1922189117 pmid: 32817490
[12]	Di Vincenzo F, Puca P, Lopetuso LR, et al. Bile acid-related regulation of mucosal inflammation and intestinal motility: From pathogenesis to therapeutic application in IBD and microscopic colitis[J]. Nutrients, 2022, 14(13): 2664. doi: 10.3390/nu14132664 URL
[13]	Hvas CL, Dahl Jørgensen SM, Jørgensen SP, et al. Fecal microbiota transplantation is superior to fidaxomicin for treatment of recurrent Clostridium difficile infection[J]. Gastroenterology, 2019, 156(5): 1324-1332.e3. doi: S0016-5085(18)35434-9 pmid: 30610862
[14]	Lee CH, Steiner T, Petrof EO, et al. Frozen vs fresh fecal microbiota transplantation and clinical resolution of diarrhea in patients with recurrent Clostridium difficile infection: A randomized clinical trial[J]. JAMA, 2016, 315(2): 142-149. doi: 10.1001/jama.2015.18098 pmid: 26757463
[15]	Kassam Z, Dubois N, Ramakrishna B, et al. Donor screening for fecal microbiota transplantation[J]. N Engl J Med, 2019, 381(21): 2070-2072. doi: 10.1056/NEJMc1913670 URL
[16]	Park H, Laffin MR, Jovel J, et al. The success of fecal microbial transplantation in Clostridium difficile infection correlates with bacteriophage relative abundance in the donor: A retrospective cohort study[J]. Gut Microbes, 2019, 10(6): 676-687. doi: 10.1080/19490976.2019.1586037 URL
[17]	Zuo T, Wong SH, Lam K, et al. Bacteriophage transfer during faecal microbiota transplantation in Clostridium difficile infection is associated with treatment outcome[J]. Gut, 2018, 67(4): 634-643.
[18]	Kazemian N, Ramezankhani M, Sehgal A, et al. The trans-kingdom battle between donor and recipient gut microbiome influences fecal microbiota transplantation outcome[J]. Sci Rep, 2020, 10(1): 18349. doi: 10.1038/s41598-020-75162-x pmid: 33110112
[19]	Jiang ZD, Jenq RR, Ajami NJ, et al. Safety and preliminary efficacy of orally administered lyophilized fecal microbiota product compared with frozen product given by enema for recurrent Clostridium difficile infection: A randomized clinical trial[J]. PLoS One, 2018, 13(11): e0205064. doi: 10.1371/journal.pone.0205064 URL
[20]	Ianiro G, Masucci L, Quaranta G, et al. Randomised clinical trial: Faecal microbiota transplantation by colonoscopy plus vancomycin for the treatment of severe refractory Clostridium difficile infection-single versus multiple infusions[J]. Aliment Pharmacol Ther, 2018, 48(2): 152-159. doi: 10.1111/apt.14816 URL
[21]	Ianiro G, Maida M, Burisch J, et al. Efficacy of different faecal microbiota transplantation protocols for Clostridium difficile infection: A systematic review and meta-analysis[J]. United European Gastroenterol J, 2018, 6(8): 1232-1244. doi: 10.1177/2050640618780762 URL
[22]	Kao D, Roach B, Silva M, et al. Effect of oral capsule-vs colonoscopy-delivered fecal microbiota transplantation on recurrent Clostridium difficile infection: A randomized clinical trial[J]. JAMA, 2017, 318(20): 1985-1993. doi: 10.1001/jama.2017.17077 URL
[23]	Rapoport EA, Baig M, Puli SR. Adverse events in fecal microbiota transplantation: A systematic review and meta-analysis[J]. Ann Gastroenterol, 2022, 35(2): 150-163.
[24]	Defilipp Z, Bloom PP, Torres Soto M, et al. Drug-resistant E.coli bacteremia transmitted by fecal microbiota transplant[J]. N Engl J Med, 2019, 381(21): 2043-2050. doi: 10.1056/NEJMoa1910437 URL
[25]	Zellmer C, Sater MRA, Huntley MH, et al. Shiga toxin-producing Escherichia coli transmission via fecal microbiota transplant[J]. Clin Infect Dis, 2021, 72(11): e876-e880. doi: 10.1093/cid/ciaa1486 pmid: 33159210
[26]	Orenstein R, Dubberke E, Hardi R, et al. Safety and durability of RBX2660 (microbiota suspension) for recurrent Clostridium difficile infection: Results of the PUNCH CD Study[J]. Clin Infect Dis, 2016, 62(5): 596-602. doi: 10.1093/cid/civ938 pmid: 26565008
[27]	Dubberke ER, Lee CH, Orenstein R, et al. Results from a randomized, placebo-controlled clinical trial of a RBX2660-A microbiota-based drug for the prevention of recurrent Clostridium difficile infection[J]. Clin Infect Dis, 2018, 67(8): 1198-1204. doi: 10.1093/cid/ciy259 pmid: 29617739
[28]	Kwak S, Choi J, Hink T, et al. Impact of investigational microbiota therapeutic RBX2660 on the gut microbiome and resistome revealed by a placebo-controlled clinical trial[J]. Microbiome, 2020, 8(1): 125. doi: 10.1186/s40168-020-00907-9 pmid: 32862830
[29]	Orenstein R, Dubberke ER, Khanna S, et al. Durable reduction of Clostridioides difficile infection recurrence and microbiome restoration after treatment with RBX2660: Results from an open-label phase 2 clinical trial[J]. BMC Infect Dis, 2022, 22(1): 245. doi: 10.1186/s12879-022-07256-y pmid: 35279084
[30]	Khanna S, Pardi DS, Jones C, et al. RBX7455, a non-frozen, orally administered investigational live biotherapeutic, is safe, effective, and shifts patients' microbiomes in a phase 1 study for recurrent Clostridioides difficile infections[J]. Clin Infect Dis, 2021, 73(7): e1613-e1620. doi: 10.1093/cid/ciaa1430 pmid: 32966574
[31]	Mcgovern BH, Ford CB, Henn MR, et al. SER-109, an investigational microbiome drug to reduce recurrence after Clostridioides difficile infection: Lessons learned from a phase 2 trial[J]. Clin Infect Dis, 2021, 72(12): 2132-2140. doi: 10.1093/cid/ciaa387 pmid: 32255488
[32]	Khanna S, Pardi DS, Kelly CR, et al. A novel microbiome therapeutic increases gut microbial diversity and prevents recurrent Clostridium difficile infection[J]. J Infect Dis, 2016, 214(2): 173-181. doi: 10.1093/infdis/jiv766 pmid: 26908752
[33]	Theriot CM, Bowman AA, Young VB. Antibiotic-induced alterations of the gut microbiota alter secondary bile acid production and allow for Clostridium difficile spore germination and outgrowth in the large intestine[J]. mSphere, 2016, 1(1): e00045-00015.
[34]	Khanna S. Microbiota restoration for recurrent Clostridioides difficile: Getting one step closer every day![J]. J Intern Med, 2021, 290(2): 294-309. doi: 10.1111/joim.13290 pmid: 33856727
[35]	Sartor RB. Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: Antibiotics, probiotics, and prebiotics[J]. Gastroenterology, 2004, 126(6): 1620-1633. pmid: 15168372
[36]	Plaza-Diaz J, Ruiz-Ojeda FJ, Gil-Campos M, et al. Immune-mediated mechanisms of action of probiotics and synbiotics in treating pediatric intestinal diseases[J]. Nutrients, 2018, 10(1): 42. doi: 10.3390/nu10010042 URL
[37]	Hudson LE, Anderson SE, Corbett AH, et al. Gleaning insights from fecal microbiota transplantation and probiotic studies for the rational design of combination microbial therapies[J]. Clin Microbiol Rev, 2017, 30(1): 191-231. pmid: 27856521
[38]	Mills JP, Rao K, Young VB. Probiotics for prevention of Clostridium difficile infection[J]. Curr Opin Gastroenterol, 2018, 34(1): 3-10. doi: 10.1097/MOG.0000000000000410 URL
[39]	Koh E, Hwang IY, Lee HL, et al. Engineering probiotics to inhibit Clostridioides difficile infection by dynamic regulation of intestinal metabolism[J]. Nat Commun, 2022, 13(1): 3834. doi: 10.1038/s41467-022-31334-z pmid: 35787625
[40]	Wang L, Cao H, Liu L, et al. Activation of epidermal growth factor receptor mediates mucin production stimulated by p40, a Lactobacillus rhamnosus GG-derived protein[J]. J Biol Chem, 2014, 289(29): 20234-20244. doi: 10.1074/jbc.M114.553800 pmid: 24895124
[41]	Wan LY, Chen ZJ, Shah NP, et al. Modulation of intestinal epithelial defense responses by probiotic bacteria[J]. Crit Rev Food Sci Nutr, 2016, 56(16): 2628-2641. doi: 10.1080/10408398.2014.905450 pmid: 25629818
[42]	Gunaratnam S, Diarra C, Paquette PD, et al. The acid-dependent and independent effects of lactobacillus acidophilus CL1285, Lacticaseibacillus casei LBC80R, and Lacticaseibacillus rhamnosus CLR2 on Clostridioides difficile R20291[J]. Probiotics Antimicrob Proteins, 2021, 13(4): 949-956. doi: 10.1007/s12602-020-09729-5 pmid: 33492661
[43]	Shen NT, Maw A, Tmanova LL, et al. Timely use of probiotics in hospitalized adults prevents Clostridium difficile infection: A systematic review with meta-regression analysis[J]. Gastroenterology, 2017, 152(8): 1889-1900. doi: S0016-5085(17)30136-1 pmid: 28192108
[44]	Chen K, Zhu Y, Zhang Y, et al. A probiotic yeast-based immunotherapy against Clostridioides difficile infection[J]. Sci Transl Med, 2020, 12(567): aax4905.
[45]	Gerding DN, Meyer T, Lee C, et al. Administration of spores of nontoxigenic Clostridium difficile strain M3 for prevention of recurrent C.difficile infection: A randomized clinical trial[J]. JAMA, 2015, 313(17): 1719-1727. doi: 10.1001/jama.2015.3725 pmid: 25942722

肠道微生物群疗法防治复发性艰难梭菌感染研究进展

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 45

相关文章 15

编辑推荐

Metrics

本文评价

[1]	张晓璐, 李红山. 自身免疫性肝炎发病机制研究进展——聚焦“肠道菌群与免疫系统相互作用”[J]. 临床荟萃, 2024, 39(2): 177-182.
[2]	杨小雄, 杨帆, 魏小果. 肠-微生物群-肝轴与代谢相关脂肪性肝病的研究进展[J]. 临床荟萃, 2023, 38(6): 559-563.
[3]	徐文灯, 沈懿, 张小峰. 心电图非特异性ST-T异常与急性缺血性脑卒中复发的相关性[J]. 临床荟萃, 2023, 38(10): 883-886.
[4]	周耀, 魏博涛. 锌辅助治疗小儿轮状病毒肠炎及对短期复发影响的Meta分析[J]. 临床荟萃, 2022, 37(2): 106-113.
[5]	李青, 邓琦. 嵌合抗原受体T细胞治疗复发难治弥漫大B细胞淋巴瘤进展[J]. 临床荟萃, 2022, 37(2): 182-187.
[6]	杜菲, 李英. 老年糖尿病肾病患者肠道菌群失调的研究进展[J]. 临床荟萃, 2022, 37(2): 178-181.
[7]	李卫伟, 李亚男. 左房容积指数用于预测心房颤动患者射频消融后复发的meta分析[J]. 临床荟萃, 2022, 37(11): 965-968.
[8]	杨燕, 王德峰. 肠道菌群在糖尿病治疗中的研究进展[J]. 临床荟萃, 2022, 37(10): 953-956.
[9]	安景景, 王小娟, 邓爱云. 预激综合征伴心房颤动射频消融术后心房颤动复发率的meta分析[J]. 临床荟萃, 2022, 37(10): 899-904.
[10]	王延旭，刘苗，张瑞星. Ⅳ型胃神经内分泌肿瘤的临床病理特征及影响术后复发的危险因素分析[J]. 临床荟萃, 2020, 35(9): 805-810.
[11]	郑涵露, 赵小英. CD5阳性弥漫大B细胞淋巴瘤研究进展[J]. 临床荟萃, 2020, 35(3): 282-288.
[12]	赵学刚1，刘晓敏1，李丽1，周炜2. 肌骨超声检查对临床缓解类风湿关节炎患者疾病复发的预测价值[J]. 临床荟萃, 2019, 34(9): 802-804.
[13]	诺扎·代尼尔，木胡牙提. 心房颤动射频消融术后复发影响因素的荟萃分析[J]. 临床荟萃, 2019, 34(3): 267-272.
[14]	杨婷婷1，王艳艳1，王宝宏2. 外周血淋巴细胞和单核细胞比值对预测弥漫大B细胞淋巴瘤复发的研究[J]. 临床荟萃, 2019, 34(12): 1089-1093.
[15]	刘方, 张学军, 牛志云, 温树鹏, 王颖, 王福旭. 异基因造血干细胞移植后嵌合状态与白血病复发关系的研究[J]. 临床荟萃, 2019, 34(12): 1076-1080.